**Long-acting somatostatin analogue treatments in Autosomal Dominant Polycystic Kidney Disease and Polycystic Liver Disease: A systematic review and meta-analysis**

**– Supplementary figures**

**Authors:** Joshua D Griffiths[1] MBChB, Mark T Mills[1] MBChB, Albert CM Ong[1] DM

**Author affiliations**: [1]Kidney Genetics Group, Academic Unit of Nephrology, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK

**Corresponding author:** Dr. Joshua Griffiths, Academic Nephrology Unit, Department of Infection Immunity and Cardiovascular Disease, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK. Email: jgriffiths1@doctors.org.uk

**Supplementary Table 1:** Electronic search strategy

**Supplementary Figure 1.** Funnel plots for primary outcomes

**Supplementary Figure 2.** Somatostatin treatment reduces change from baseline TKV

**Supplementary Figure 3.** Somatostatin treatment has no effect on diastolic and systolic blood pressure or progression to ESRF

| Database | Terms |
|---|---|
| PUBMED | ADPKD<br>PKD<br>Polycystic kidney disease<br>PLD<br>Polycystic liver disease<br>+<br>Somatostatin<br>Octreotide<br>Lanreotide |
| Clinicaltrials.gov | ADPKD<br>PKD<br>Polycystic kidney disease<br>PLD<br>Polycystic liver disease<br>+<br>Somatostatin<br>Octreotide<br>Lanreotide |
| *Cochrane* Central Register of Controlled Trials | ADPKD<br>PKD<br>Polycystic kidney disease<br>PLD<br>Polycystic liver disease<br>+<br>Somatostatin<br>Octreotide<br>Lanreotide |

**Supplementary Table 1:** electronic search strategy

**a.**




**b.**




**c.**




**Supplementary Figure 1.** Funnel plots for primary outcomes; eGFR (a), TKV (b) and TLV (c).

**a.**




**b.**




**c.**




**Supplementary Figure 2. Lanreotide treatment significantly reduced TKV and TLV but not eGFR. Ocreotide treatment does not improve TKV, TLV or eGFR.** Forest plots depicting the effects of somatostatin analogues on eGFR (a), TKV (b) and TLV (c) with trials that used Ocreotide separated from trials which used Lanreotide. Horizontal lines represent the 95% Confidence intervals the studies with mean difference or risk ratio indicated by coloured square. The Diamond represented pooled mean difference or risk ratio RR analysis with a 95% confidence interval.




**Supplementary Figure 3. Somatostatin treatment reduces change from baseline TKV.** Forest plots depicting the effects of Somatostatin analogue vs controls on TKV when change from baseline means are used to correct for heterogeneity and variability in initial TKV's. Horizontal lines represent the 95% confidence intervals the studies with mean difference indicated by coloured square. The Diamond represented pooled mean difference analysis with a 95% confidence interval.

**a.**




**b.**




**c.**




**Supplementary Figure 4. Somatostatin treatment has no effect on diastolic and systolic blood pressure or progression to ESRF.** Forest plots depicting the effects of Somatostatin analogue vs controls on Systolic blood pressure (a), Diastolic blood pressure (b) and progression to ESRF (c). Horizontal lines represent the 95% Confidence intervals the studies with mean difference or risk ratio indicated by coloured square. The Diamond represented pooled mean difference or risk ratio RR analysis with a 95% confidence interval.